Reducing bilirubin-induced neurological dysfunction (BIND) in premature newborns, additional use of bilirubin:albumin ratio in the treatment of hyperbilirubinemia

Recruiting

• Conditions: hyperbilirubinemie en ontwikkelingsachterstand; hyperbilirubinemia; neonatal jaundice; 10028920

• Registration Number: NL-OMON30420
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 614

Inclusion Criteria

Prematurity < 32 weeks postmentrual age

Exclusion Criteria

major congenital malformations, clinical syndromes and chromosomal abnormalities

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primairy outcome variables are: neurodevelopmental outcome at 18-24 months of<br /><br>age using standardized neurological examination and mental- and psychomotor<br /><br>developmental index scores (MDI and PDI).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome variables are peak TSB, peak B:A ratio, duration of<br /><br>hyperbilirubinemia, number and duration of phototherapy, number exchange<br /><br>transfusions, and the standard complications of prematurity such as mortality,<br /><br>RDS, BPD, ROP, NEC, IVH, PVE/PVL etcetera.</p><br>